Inpharma 1370 - 18 Jan 2003 Olmesartan medoxomil good value for hypertension in the US Olmesartan medoxomil can potentially reduce the overall cost of medical care among patients with uncontrolled hypertension, compared with other leading angiotensin II receptor antagonists (AIIRAs) in a US managed-care setting, according to research from that country. Direct costs and outcomes were compared between once-daily olmesartan medoxomil 20mg and once-daily losartan 50mg, valsartan 80mg or irbesartan 150mg among a hypothetical cohort of 100 000 patients with hypertension over a 5-year period. * The evaluation was based on results from a double-blind, prospective, randomised trial comparing the efficacy of the four AIIRAs, the Framingham Heart Study and data from a large managed-care database. Analyses based on absolute reductions in diastolic BP showed that olmesartan medoxomil would lead to fewer new cases of cardiovascular (CV) disease, resulting in a total incremental cost reduction of more than $US15.1 million, $US16.2 million and $US5.4 million, compared with losartan, valsartan and irbesartan, respectively, over 5 years. ** In addition, fewer cases of coronary heart disease would occur with olmesartan medoxomil, leading to a total incremental cost reduction of around $US11.1 million, $US12 million and $US4 million, compared with losartan, valsartan and irbesartan, respectively, and fewer myocardial infarctions would result in a respective incremental cost reduction of around $US4.1 million, $US4.5 million and $US1.4 million. Benefits were not additive and similar drug acquisition costs were assumed. * Funding for the study was provided by Sankyo Pharma Inc. ** Costs (1997–1999 values) were those associated with the treatment of CV events, including hospitalisations, emergency-room and physician visits, outpatient services and prescription medications, and were assessed from a US managed-care perspective. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan potassium, valsartan, and irbesartan. PharmacoEconomics 21: 61-74, No. 1, 2003 800882705 1 Inpharma 18 Jan 2003 No. 1370 1173-8324/10/1370-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Olmesartan medoxomil good value for hypertension in the US

Download PDF Report

View
213
Download
1

Embed Size (px)

Citation preview

Inpharma 1370 - 18 Jan 2003

Olmesartan medoxomil good valuefor hypertension in the US

Olmesartan medoxomil can potentially reduce theoverall cost of medical care among patients withuncontrolled hypertension, compared with otherleading angiotensin II receptor antagonists (AIIRAs) in aUS managed-care setting, according to research fromthat country.

Direct costs and outcomes were compared betweenonce-daily olmesartan medoxomil 20mg and once-dailylosartan 50mg, valsartan 80mg or irbesartan 150mgamong a hypothetical cohort of 100 000 patients withhypertension over a 5-year period.* The evaluation wasbased on results from a double-blind, prospective,randomised trial comparing the efficacy of the fourAIIRAs, the Framingham Heart Study and data from alarge managed-care database.

Analyses based on absolute reductions in diastolic BPshowed that olmesartan medoxomil would lead to fewernew cases of cardiovascular (CV) disease, resulting in atotal incremental cost reduction of more than $US15.1million, $US16.2 million and $US5.4 million, comparedwith losartan, valsartan and irbesartan, respectively,over 5 years.**

In addition, fewer cases of coronary heart diseasewould occur with olmesartan medoxomil, leading to atotal incremental cost reduction of around $US11.1million, $US12 million and $US4 million, comparedwith losartan, valsartan and irbesartan, respectively, andfewer myocardial infarctions would result in a respectiveincremental cost reduction of around $US4.1 million,$US4.5 million and $US1.4 million. Benefits were notadditive and similar drug acquisition costs wereassumed.* Funding for the study was provided by Sankyo Pharma Inc.** Costs (1997–1999 values) were those associated with thetreatment of CV events, including hospitalisations, emergency-roomand physician visits, outpatient services and prescription medications,and were assessed from a US managed-care perspective.

Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers ina US managed care setting: olmesartan medoxomil compared with losartanpotassium, valsartan, and irbesartan. PharmacoEconomics 21: 61-74, No. 1,2003 800882705